- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00442377
Study to Investigate the Induction of an Protective Immune Response to Malaria
Exposure of Human Volunteers to Live Malaria Sporozoites Under Chloroquine Prophylaxis
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Efforts to develop vaccines against malaria still represent a substantial focus of current research activities. Factors that have hampered the development of a subunit vaccine include the complexity of the malaria life cycle, the wide variety of immune response induced by the malaria parasite, and an incomplete knowledge of protective immunity. This study is therefore aimed at inducing protective immunity against malaria in 15 healthy volunteers. Volunteers will be exposed to the bites of infectious mosquitoes 3 times with live P. falciparum sporozoites under chloroquine prophylaxis. Challenge with infected mosquitoes will be given after stopping chloroquine prophylaxis.
Five volunteers will form a control group; they will be exposed to non-infectious mosquitoes under chloroquine prophylaxis.
Endpoints include the time and height of parasitemia after challenge, the development of fever and immunological parameters.
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Nijmegen, Nederland, 6500 HB
- Radboud University Nijmegen Medical Centre
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age > 18 and < 45 years healthy volunteers (males or females).
- General good health based on history and clinical examination.
- All volunteers have to sign the informed consent form.
- Negative pregnancy test.
- Use of adequate contraception for females
- Reachable by phone during the whole study period.
- Volunteer agrees to inform the general practitioner and agrees to sign a request for medical information concerning contra-indications for participation in the trial
Exclusion Criteria:
- History of malaria or residence in malaria endemic areas within the past six months.
- Positive serology for P. falciparum
- Previously participated in any malaria vaccine study
- Symptoms, physical signs and laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the study results or compromise the health of the volunteers.
- Cardiovascular risk >10% according to European guidelines, taking into account sex, age, cholesterol, weight, smoking habits, blood pressure, diabetes
- Any laboratory abnormalities on screened blood samples beyond the normal range, as defined at UMC St Radboud. Positive HIV, HBV or HCV tests.
- Volunteers should not be enrolled in any other clinical trial during the whole trial period.
- Volunteers should not receive chronic medication, especially immunosuppressive agents (steroids, immunomodulating or immunosuppressive drugs) during the three months preceding the screening visit or during the study period.
- Pregnant or lactating women.
- Volunteers unable to give written informed consent.
- Volunteers unable to be closely followed for social, geographic or psychological reasons.
- Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the study.
- Known hypersensitivity for anti-malaria drugs
- Volunteers are not allowed to travel to malaria endemic countries during the study period.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
---|
A significant difference in time of thick smear positivity between exposed and control groups
|
A significant difference in parasitemia as measured by 18S Pf NASBA between exposed and control group
|
A significant difference in kinetics of parasitemia between exposed and control groups as measured by 18S Pf NASBA.
|
A difference in occurrence or height of fever between exposed and control groups.
|
Secundaire uitkomstmaten
Uitkomstmaat |
---|
Significant differences in immune response between exposed and control volunteers (including NK-cell reactivity, TLR reactivity and regulatory T-cell reactivity)
|
Significant differences in the outcome of in vitro functional malaria assays between exposed and control volunteers
|
Significant differences in cellular reactivity against Pf antigens
|
Significant differences in parasite VAR gene expression during infection
|
The identification of immune mechanisms that correlate with protection
|
6. The identification of potential vaccine candidates that correlate with protection
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Robert Sauerwein, Prof, Radboud University Medical Center
Publicaties en nuttige links
Algemene publicaties
- Coffeng LE, Hermsen CC, Sauerwein RW, de Vlas SJ. The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection. PLoS Comput Biol. 2017 Jan 12;13(1):e1005255. doi: 10.1371/journal.pcbi.1005255. eCollection 2017 Jan.
- Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, Renia L, van der Ven A, Hermsen CC, Sauerwein R. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009 Jul 30;361(5):468-77. doi: 10.1056/NEJMoa0805832.
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- EHMI-8
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Falciparum-malaria
-
University of OxfordBeëindigdP. Falciparum-malariaThailand
-
National Institute of Allergy and Infectious Diseases...VoltooidAccute Falciparum-malariaMali
-
Medical University of ViennaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Armed Forces...VoltooidOngecompliceerde Falciparum-malariaBangladesh
-
Medecins Sans Frontieres, NetherlandsUniversity of Oxford; Mahidol University; Disease Control, Department of Health...OnbekendOngecompliceerde Falciparum-malariaMyanmar
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanVoltooidVivax-malaria | Ongecompliceerde Falciparum-malariaAfganistan
-
University of OxfordNanyang Technological University; Texas Biomedical Research InstituteVoltooidP. Falciparum-malaria | P. Falciparum Malaria Gemengde infectieThailand
-
Novartis PharmaceuticalsWervingOngecompliceerde Plasmodium Falciparum MalariaIvoorkust, Kenia, Ghana, Oeganda
-
Medicines for Malaria VentureVoltooidOngecompliceerde Plasmodium Falciparum MalariaOeganda, Benin, Burkina Faso, Congo, de Democratische Republiek van de, Gabon, Mozambique, Vietnam
-
University of OxfordMahidol Oxford Tropical Medicine Research Unit; Department of Medical Research...IngetrokkenOngecompliceerde Falciparum-malaria | Artemisinine-resistent
-
Karolinska University HospitalMuhimbili University of Health and Allied SciencesVoltooidOngecompliceerde Plasmodium Falciparum MalariaTanzania